SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) January 15, 2002
Generex Biotechnology Corporation
---------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 000-25169 82-049021
-------- -------- ---------
(State or other jurisdiction (Commission (IRS Employer
of Incorporation) File Number) Identification No.)
33 Harbor Square, Suite 202, Toronto, Ontario Canada M5J 2G2
---------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code 416/364-2551
------------
---------------------------------------------------------------------------
(Former name or former address, if changed since last report)
Item 7. Exhibits
*10.1 Amended and Restated Subscription, Joint Development and Operating
Agreement dated January 15, 2002, between Elan Corporation, plc, Elan
International Services, Ltd. and Generex Biotechnology Corporation and
Generex (Bermuda), Ltd.
*10.2 Amended and Restated License Agreement dated January 15, 2002, between
Elan Corporation, plc and Generex (Bermuda), Ltd.
*10.3 Amended and Restated License Agreement dated January 15, 2002, between
Generex Biotechnology Corporation and Generex (Bermuda), Ltd.
* Portions of this exhibit have been omitted pursuant to a request for
confidential treatment.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
GENEREX BIOTECHNOLOGY CORPORATION
Dated: July 17, 2003 By: /s/ Rose C. Perri
-----------------------------------------------
Rose C. Perri, Chief Operating Officer